GOLDMAN SACHS GROUP INC

Position in CADL — Candel Therapeutics, Inc.

CIK 886982 NEW YORK, NY

Position in CADL

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$1,114,852

+$747,123 QoQ

Shares Held

227,521

+249.6% QoQ

Ownership

0.311%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Dec 2021

11 quarters on record

Voting authority Sole 99.98901200328761.ToString("F0")% Shared 0.ToString("F0")% None 0.010987996712391384.ToString("F0")%

Healthcare · as of Mar 31, 2026

GOLDMAN SACHS GROUP INC holds $10,294,260,512 across 365 Biotechnology names. CADL ranks #251 (0.0% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	2,417,875	$1,079,677,898
2	REGN	Regeneron Pharmaceuticals, Inc.	1,300,558	$1,004,863,129
3	MRNA	Moderna, Inc.	6,603,697	$335,467,805
4	ROIV	Roivant Sciences Ltd.	11,111,591	$307,791,069
5	PRAX	Praxis Precision Medicines, Inc.	710,734	$228,991,385
6	INCY	Incyte Corp	2,351,221	$221,296,919
7	RVMD	Revolution Medicines, Inc.	2,185,500	$212,539,874
8	RYTM	Rhythm Pharmaceuticals, Inc.	1,965,432	$170,933,620

11 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$1,114,852	227,521	+249.6%	Shares	Defined	2026-05-15
2025-12-31	$367,729	65,085	+80.7%	Shares	Defined	2026-03-25
2025-09-30	$183,706	36,021	-54.6%	Shares	Defined	2025-11-14
2025-06-30	$401,789	79,405	+45.3%	Shares	Defined	2025-08-14
2025-03-31	$308,862	54,666	-16.2%	Shares	Defined	2025-06-27
2024-12-31	$566,247	65,236	+115.6%	Shares	Defined	2025-02-11
2024-09-30	$209,708	30,261	+66.0%	Shares	Defined	2024-11-14
2024-06-30	$112,995	18,225	+81.6%	Shares	Defined	2024-08-13
2022-06-30	$32,519	10,037	-4.5%	Shares	Defined	2024-05-14
2022-03-31	$53,495	10,510	-0.8%	Shares	Defined	2022-05-16
2021-12-31	$82,837	10,593	—	Shares	Defined	2022-02-17
No filing history on record for this holder in this stock.